(Q38011881)

27 August 2017

title

The impact of antibodies in late-onset Pompe disease: a case series and literature review (English)

1 reference

27 August 2017

1 reference

Trusha T Patel

1

1 reference

27 August 2017

Suhrad G Banugaria

2

1 reference

27 August 2017

Laura E Case

3

1 reference

27 August 2017

Stephan Wenninger

4

1 reference

27 August 2017

Benedikt Schoser

5

1 reference

27 August 2017

Priya S Kishnani

6

1 reference

27 August 2017

language of work or name

1 reference

9 May 2012

1 reference

Molecular Genetics and Metabolism

27 August 2017

published in

1 reference

27 August 2017

volume

106

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

301-309

1 reference

A randomized study of alglucosidase alfa in late-onset Pompe's disease

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Atypical immunologic response in a patient with CRIM-negative Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Pompe disease diagnosis and management guideline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Glycogenosis type II: a juvenile-specific mutation with an unusual splicing pattern and a shared mutation in African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Human immune response to recombinant human proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Enzyme-replacement therapy in mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Advances in hemophilia: experimental aspects and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Epitope spreading: protection from pathogens, but propagation of autoimmunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

Elimination of antibodies to recombinant enzyme in Pompe's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.04.027

10.1016/J.YMGME.2012.04.027

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference